» Articles » PMID: 38243713

RNF213 in Moyamoya Disease: Genotype-phenotype Association and the Underlying Mechanism

Overview
Specialty General Medicine
Date 2024 Jan 20
PMID 38243713
Authors
Affiliations
Soon will be listed here.
Abstract

Moyamoya disease (MMD) is a cerebrovascular disorder characterized by a steno-occlusive internal carotid artery and compensatory vascular network formation. Although the precise pathogenic mechanism remains elusive, genetic association studies have identified RNF213 as the principal susceptibility gene for MMD, with the single nucleotide polymorphism p.R4810K recognized as the founder variant predominantly in the Asian populations. Distinct genotype-phenotype correlations are observable in RNF213 -related MMD. The clinical manifestations linked to p.R4810K bear commonalities within Asian cohort, including familial predisposition, earlier age of onset, ischemic episodes, and involvement of the posterior cerebral artery (PCA). However, despite these shared phenotypic characteristics, there is significant heterogeneity in RNF213 -related MMD presentations. This diversity manifests as variations across ethnic groups, inconsistent clinical symptoms and prognosis, and occurrence of other vasculopathies involving RNF213 . This heterogeneity, in conjunction with the observed low disease penetrance of RNF213 mutations, suggests that the presence of these mutations may not be sufficient to cause MMD, underscoring the potential influence of other genetic or environmental factors. Although the current research might not have fully identified these additional contributors, experimental evidence points toward the involvement of RNF213 in angiogenesis, lipid metabolism, and the immune response. Future research is required to unveil the molecular mechanisms and identify the factors that synergize with RNF213 in the pathogenesis of MMD.

Citing Articles

The Role of Immune Cells in Moyamoya Disease.

Wang S, Jiang Q, Liu Y, Zhang X, Huang Y, Zhang H Brain Sci. 2025; 15(2).

PMID: 40002470 PMC: 11852451. DOI: 10.3390/brainsci15020137.


Serum Creatine Levels as a Predictive Factor for Postoperative Cerebrovascular Events in Patients With Moyamoya Disease.

Mou S, Zhao Z, Liu C, Li J, He Q, Liu W Brain Behav. 2025; 15(2):e70331.

PMID: 39935209 PMC: 11814481. DOI: 10.1002/brb3.70331.


Identification of oxidative phosphorylation-related genes in moyamoya disease by combining bulk RNA-sequencing analysis and machine learning.

Han Z, Zhang J, Su Y, Zhou Z, Wang Y, Xu S Front Genet. 2024; 15:1417329.

PMID: 38919950 PMC: 11197386. DOI: 10.3389/fgene.2024.1417329.

References
1.
Sarkar P, Thirumurugan K . New insights into TNFα/PTP1B and PPARγ pathway through RNF213- a link between inflammation, obesity, insulin resistance, and Moyamoya disease. Gene. 2020; 771:145340. DOI: 10.1016/j.gene.2020.145340. View

2.
Scott R, Smith E . Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009; 360(12):1226-37. DOI: 10.1056/NEJMra0804622. View

3.
Cecchi A, Guo D, Ren Z, Flynn K, Santos-Cortez R, Leal S . RNF213 rare variants in an ethnically diverse population with Moyamoya disease. Stroke. 2014; 45(11):3200-7. PMC: 4420622. DOI: 10.1161/STROKEAHA.114.006244. View

4.
Kobayashi H, Brozman M, Kyselova K, Viszlayova D, Morimoto T, Roubec M . RNF213 Rare Variants in Slovakian and Czech Moyamoya Disease Patients. PLoS One. 2016; 11(10):e0164759. PMC: 5063318. DOI: 10.1371/journal.pone.0164759. View

5.
Thery F, Martina L, Asselman C, Zhang Y, Vessely M, Repo H . Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity. Nat Commun. 2021; 12(1):5772. PMC: 8486878. DOI: 10.1038/s41467-021-26061-w. View